deltatrials
Completed PHASE1 NCT00006024

Temozolomide Plus Lomustine Followed by Radiation Therapy in Treating Patients With High-Grade Malignant Glioma

A Phase I Study of Temozolomide and CCNU in Pediatric Patients With Newly Diagnosed Incompletely Resected Non-Brainstem High-Grade Gliomas

Sponsor: Children's Oncology Group

Conditions Brain Tumor Central Nervous System Tumor
Interventions lomustine temozolomide
Updated 7 times since 2017 Last updated: Feb 11, 2014 Started: Nov 30, 2000 Primary completion: Jan 31, 2005 Completion: Sep 30, 2006

This PHASE1 trial investigates Brain Tumor and Central Nervous System Tumor and is currently completed. Children's Oncology Group leads this study, which shows 7 recorded versions since 2000 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Change History

7 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE1

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE1

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE1

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE1

▶ Show 2 earlier versions

  1. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE1

  2. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE1

    First recorded

Nov 2000

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Children's Oncology Group
  • National Cancer Institute (NCI)
Data source: Children's Oncology Group

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Akron, United States, Albany, United States, Albuquerque, United States, Amarillo, United States, Ann Arbor, United States, Asheville, United States, Atlanta, United States, Auckland, New Zealand, Augusta, United States, Austin, United States and 167 more location s